ArticleCancer cell international2026
miR-484 sensitizes in IDH-wild and IDH-mutant glioblastoma cells to temozolomide by inhibiting oncogenic FOXM1 signaling.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is the most diagnosed primary brain tumor with an extremely poor survival rate. Emerging evidence suggests that miRNAs are involved in GBM tumorigenesis. miR-484 was highly expressed in glioma cells and enhanced cell migration, and invasion. However, the role of miR-484 in GBM and its downstream targets are not well understood.
methodsWe analyzed miR-484 expression in GBM patient tissue samples (IDH wild-type and IDH-mutant) and cell lines via Real-Time PCR. In GBM cells transfected with inhibitor- and mimic-miR-484, we investigated cell proliferation, migration, invasion, cell cycle, and apoptosis. Additionally, protein expression of FOXM1 and its downstream targets were investigated. RNA-seq analysis was performed on mimic-miR-484-transfected U87-MG and IDH1-mutant-U87 cells.
resultsmiR-484 expression was higher in IDH-mutant patient tumors compared to IDH1-wild type patient tumors. Ectopic expression of miR-484 suppressed cell proliferation, colony formation, migration and invasion, and induced apoptosis in GBM cells. Furthermore, we found that miR-484 suppresses FOXM1 and its downstream targets including Integrin-β1/FAK/Src and Cyclin-D and PARP, all of which have been shown to be potential therapeutic targets in GBM cells. In addition, expression of miR-484 enhanced TMZ-induced FOXM1 downregulation in GBM.
conclusionOur findings suggest for the first time that miR-484 act as a tumor suppressor in IDH1-wild type and mutant GBM cells by targeting FOXM1 oncogenic transcription factor and its downstream in GBM cells. Therefore, miR-484-based treatment may provide a new avenue for controlling GMB growth and progression and may enhance the therapeutic efficacy of TMZ. Trial registry: decision no: 2019/247.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.